Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Securities

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet.CA reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a research report on Friday, March 28th.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock opened at $0.80 on Tuesday. Milestone Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $2.75. The company’s 50 day moving average price is $1.92 and its two-hundred day moving average price is $1.82. The stock has a market cap of $42.85 million, a P/E ratio of -0.99 and a beta of 1.83. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MIST. Jones Financial Companies Lllp lifted its stake in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. National Bank of Canada FI lifted its position in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after buying an additional 11,600 shares during the last quarter. PVG Asset Management Corp purchased a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $46,000. Cubist Systematic Strategies LLC bought a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth $73,000. Finally, XTX Topco Ltd purchased a new stake in Milestone Pharmaceuticals in the 4th quarter worth about $80,000. 86.18% of the stock is owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.